Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients who are relapsed or refractory to checkpoint inhibitors, a multi-billion dollar drug class hampered by widespread ...

The ASH oral presentation today reports data from the ongoing dose escalation and dose expansion parts of the CARDINAL study of TERN-701 in patients with previously treated CML. As of the September 13 ...

IBI3003 is a novel trispecific antibody targeting GPRC5D, BCMA and CD3 simultaneously. Its dual-targeting design against BCMA and GPRC5 aims to overcome single antigen escape in multiple myeloma (MM).

Gov Hyacinth Iormem Alia of Benue State has said that he is determined to fix the broken Benue, some indigenes believed him ...

Presentation included previously disclosed primary results from the pivotal ARES Phase 3 single-arm trial evaluating MaaT013 (Xervyteg) in treating refractory severe acute Graft-versus-Host Disease ...

Discusses Strategic Portfolio Update and Leadership Transition December 8, 2025 9:00 AM ESTCompany ParticipantsJohn Nypaver - ...

Rusfertide was generally well-tolerated through 52 Weeks of treatment. The most common treatment-emergent adverse events (AE) in rusfertide-treated patients were injection site reactions (47.4%), ...

MPACT’s VivoCity reported positive rental reversion of 14.1% in 2QFY2026 ended Sept 30. UOBKH thinks MPACT will be acquired ...

Syndax Pharmaceuticals, Inc. ( SNDX) The 67th American Society of Hematology ( ASH) Annual Meeting December 8, 2025 7:00 AM EST ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY ® (exagamglogene autotemcel) in people ages 5 years and ...

The slow pace of the federal antitrust suit lodged against NASCAR continued Monday at the start of the second week of the ...

Detailed price information for Assembly Biosciences (ASMB-Q) from The Globe and Mail including charting and trades.